Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Rated "Hold" by Sell-Side Analysts

Key Points

• Analysts rate Medpace “Hold” on average: Nine of 12 brokerages recommend holding the stock, while three recommend buying it. The average 12-month price target is $595.20, below the recent share price of $615.94.
• Medpace exceeded quarterly expectations: The company reported adjusted earnings of $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million.
• Insiders have been selling shares: Company insiders sold 284,909 shares worth approximately $176.1 million over the past quarter, while institutional investors continue to own a substantial 77.98% of the stock.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have received an average rating of "Hold" from the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $595.20.

MEDP has been the topic of a number of recent analyst reports. TD Cowen raised their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Royal Bank Of Canada increased their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th.

Medpace Trading Down 0.5%

Shares of Medpace stock opened at $615.94 on Tuesday. The company has a market capitalization of $17.19 billion, a P/E ratio of 36.10, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The stock has a fifty day simple moving average of $596.41 and a 200 day simple moving average of $517.30. Medpace has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same period last year, the business earned $3.10 EPS. The business's revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace will post 17.54 EPS for the current year.

Insiders Place Their Bets

In other news, Director Robert O. Kraft sold 3,858 shares of the firm's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the completion of the sale, the director directly owned 955 shares of the company's stock, valued at $590,008.55. This trade represents a 80.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 27,833 shares of Medpace stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $621.33, for a total value of $17,293,477.89. Following the sale, the chief executive officer owned 389,456 shares in the company, valued at $241,980,696.48. The trade was a 6.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 284,909 shares of company stock worth $176,097,458 over the last quarter. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Medpace

A number of large investors have recently added to or reduced their stakes in MEDP. BlackRock Inc. bought a new position in shares of Medpace in the second quarter worth $1,323,047,000. State Street Corp boosted its stake in Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company's stock valued at $376,483,000 after buying an additional 28,666 shares during the period. Geode Capital Management LLC boosted its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock valued at $374,836,000 after buying an additional 24,625 shares during the period. Wasatch Advisors LP boosted its stake in Medpace by 19.4% during the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock valued at $371,634,000 after buying an additional 125,625 shares during the period. Finally, Renaissance Technologies LLC grew its position in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after buying an additional 38,760 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.